Assistant Professor University of Saskatchewan University of Saskatchewan Saskatoon, Saskatchewan, Canada
i. ACC/AHA and European guidelines for SAVR vs TAVI – ii. What if 80% proximal LAD lesion? 1. COMPLETE TAVR Trial vs SAVR and CABG iii. Pharmacotherapy following TAVI vs. SAVR 1. Sinus rhythm & no CAD 2. PAF with CHADS risk=1?